Filing Details
- Accession Number:
- 0001104659-19-069974
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-04 18:08:10
- Reporting Period:
- 2019-12-02
- Accepted Time:
- 2019-12-04 18:08:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1679082 | Myovant Sciences Ltd. | MYOV | () | D0 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1635088 | Ltd. Sciences Roivant | Suite 1, 3Rd Floor 11-12 St. James'S Square London X0 SW1Y 4LB | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares, Par Value $0.000017727 Per Share | Acquisiton | 2019-12-02 | 113,668 | $18.21 | 44,623,079 | No | 4 | P | Direct | |
| Common Shares, Par Value $0.000017727 Per Share | Acquisiton | 2019-12-02 | 65,525 | $18.85 | 44,688,604 | No | 4 | P | Direct | |
| Common Shares, Par Value $0.000017727 Per Share | Acquisiton | 2019-12-04 | 72,471 | $17.04 | 44,761,075 | No | 4 | P | Direct | |
| Common Shares, Par Value $0.000017727 Per Share | Acquisiton | 2019-12-04 | 2,529 | $17.56 | 44,763,604 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Footnotes
- The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $17.57 to $18.56, inclusive. The reporting person undertakes to provide to Myovant Sciences Ltd. ("Myovant"), any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4
- The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $18.57 to $19.00, inclusive. The reporting person undertakes to provide to Myovant, any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4
- The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $16.55 to $17.54 inclusive. The reporting person undertakes to provide to Myovant, any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4
- The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $17.55 to $17.56 inclusive. The reporting person undertakes to provide to Myovant, any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4
Billionaire Hedge Funds
